A tale of two systems: Lessons learned from female mid-life aging with implications for Alzheimer's prevention & treatment
- PMID: 34929348
- PMCID: PMC8884386
- DOI: 10.1016/j.arr.2021.101542
A tale of two systems: Lessons learned from female mid-life aging with implications for Alzheimer's prevention & treatment
Abstract
Neurological aging is frequently viewed as a linear process of decline, whereas in reality, it is a dynamic non-linear process. The dynamic nature of neurological aging is exemplified during midlife in the female brain. To investigate fundamental mechanisms of midlife aging that underlie risk for development of Alzheimer's disease (AD) in late life, we investigated the brain at greatest risk for the disease, the aging female brain. Outcomes of our research indicate that mid-life aging in the female is characterized by the emergence of three phases: early chronological (pre-menopause), endocrinological (peri-menopause) and late chronological (post-menopause) aging. The endocrinological aging program is sandwiched between early and late chronological aging. Throughout the three stages of midlife aging, two systems of biology, metabolic and immune, are tightly integrated through a network of signaling cascades. The network of signaling between these two systems of biology underlie an orchestrated sequence of adaptative starvation responses that shift the brain from near exclusive dependence on a single fuel, glucose, to utilization of an auxiliary fuel derived from lipids, ketone bodies. The dismantling of the estrogen control of glucose metabolism during mid-life aging is a critical contributor to the shift in fuel systems and emergence of dynamic neuroimmune phenotype. The shift in fuel reliance, puts the largest reservoir of local fatty acids, white matter, at risk for catabolism as a source of lipids to generate ketone bodies through astrocytic beta oxidation. APOE4 genotype accelerates the tipping point for emergence of the bioenergetic crisis. While outcomes derived from research conducted in the female brain are not directly translatable to the male brain, the questions addressed in a female centric program of research are directly applicable to investigation of the male brain. Like females, males with AD exhibit deficits in the bioenergetic system of the brain, activation of the immune system and hallmark Alzheimer's pathologies. The drivers and trajectory of mechanisms underlying neurodegeneration in the male brain will undoubtedly share common aspects with the female in addition to factors unique to the male. Preclinical and clinical evidence indicate that midlife endocrine aging can also be a transitional bridge to autoimmune disorders. Collectively, the data indicate that endocrinological aging is a critical period "tipping point" in midlife which can initiate emergence of the prodromal stage of late-onset-Alzheimer's disease. Interventions that target both immune and metabolic shifts that occur during midlife aging have the potential to alter the trajectory of Alzheimer's risk in late life. Further, to achieve precision medicine for AD, chromosomal sex is a critical variable to consider along with APOE genotype, other genetic risk factors and stage of disease.
Keywords: APOE; Aging; Alzheimer’s disease; Inflammation; Metabolism; Sex difference.
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.
Figures
Similar articles
-
Midlife Chronological and Endocrinological Transitions in Brain Metabolism: System Biology Basis for Increased Alzheimer's Risk in Female Brain.Sci Rep. 2020 May 22;10(1):8528. doi: 10.1038/s41598-020-65402-5. Sci Rep. 2020. PMID: 32444841 Free PMC article.
-
White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease.EBioMedicine. 2015 Nov 3;2(12):1888-904. doi: 10.1016/j.ebiom.2015.11.002. eCollection 2015 Dec. EBioMedicine. 2015. PMID: 26844268 Free PMC article.
-
Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition.Sci Rep. 2021 Jun 9;11(1):10867. doi: 10.1038/s41598-021-90084-y. Sci Rep. 2021. PMID: 34108509 Free PMC article.
-
Transitions in metabolic and immune systems from pre-menopause to post-menopause: implications for age-associated neurodegenerative diseases.F1000Res. 2020 Jan 30;9:F1000 Faculty Rev-68. doi: 10.12688/f1000research.21599.1. eCollection 2020. F1000Res. 2020. PMID: 32047612 Free PMC article. Review.
-
A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events.Rev Neurosci. 2000;11 Spec No:213-328. doi: 10.1515/revneuro.2000.11.s1.213. Rev Neurosci. 2000. PMID: 11065271 Review.
Cited by
-
A case for seeking sex-specific treatments in Alzheimer's disease.Front Aging Neurosci. 2024 Feb 13;16:1346621. doi: 10.3389/fnagi.2024.1346621. eCollection 2024. Front Aging Neurosci. 2024. PMID: 38414633 Free PMC article. Review.
-
Role of estrogen in women's Alzheimer's disease risk as modified by APOE.J Neuroendocrinol. 2023 Feb;35(2):e13209. doi: 10.1111/jne.13209. Epub 2022 Nov 24. J Neuroendocrinol. 2023. PMID: 36420620 Free PMC article. Review.
-
Estrogen receptor beta in astrocytes modulates cognitive function in mid-age female mice.Nat Commun. 2023 Sep 28;14(1):6044. doi: 10.1038/s41467-023-41723-7. Nat Commun. 2023. PMID: 37758709 Free PMC article.
-
Hypoglycemic medicines in the treatment of Alzheimer's disease: Pathophysiological links between AD and glucose metabolism.Front Pharmacol. 2023 Feb 23;14:1138499. doi: 10.3389/fphar.2023.1138499. eCollection 2023. Front Pharmacol. 2023. PMID: 36909158 Free PMC article. Review.
-
Sex Differences in Resilience and Resistance to Brain Pathology and Dysfunction Moderated by Cerebrovascular Response to Exercise and Genetic Risk for Alzheimer's Disease.J Alzheimers Dis. 2022;90(2):535-542. doi: 10.3233/JAD-220359. J Alzheimers Dis. 2022. PMID: 36155505 Free PMC article.
References
-
- Abdul-kader FF, Khedr EM, Abdel-Aleem H, Rageh TA, 2002. Effect of surgical menopause on cognitive functions. Dement Geriatr Cogn Disord 13, 193–198. - PubMed
-
- ADAPT Research Group, 2007. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68, 1800–1808. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous